Samsung Biologics Co.,Ltd.

A207940

KR7207940008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
780,000 ^KRW	-1.27%		-1.27%	+2.63%

Apr. 25	Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe	MT
Apr. 25	Samsung Biologics Posts Higher Q1 Profit, Sales	MT

Samsung Biologics to invest $1.5 billion to build a new factory in South Korea

March 16, 2023 at 10:03 pm EDT

SEOUL (Reuters) - South Korean drugmaker Samsung Biologics Co Ltd plans to invest 2 trillion won ($1.53 billion) through September 2025 to build a new factory in South Korea, the company said in a regulatory filing on Friday.

($1 = 1,304.7300 won)

(Reporting by Heekyong Yang; Editing by Muralikumar Anantharaman)

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	SAMSUNG BIOLOGICS CO.,LTD.	780,000 KRW	-1.27%	-1.27%	40.42B
	SAMSUNG ELECTRONICS CO., LTD.	76,300 KRW	-2.93%	-4.15%	370B

Latest news about Samsung Biologics Co.,Ltd.

Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe	Apr. 25	MT
Samsung Biologics Posts Higher Q1 Profit, Sales	Apr. 25	MT
Samsung Biologics Boosts Contract Size with MSD Switzerland	Apr. 08	MT
Samsung Life Science Fund Invests in Biologics Developer	Mar. 20	MT
Samsung Group Initiates Open Hiring Drive for New Talent Acquisition	Mar. 12	MT
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts; Samsung Biologics Adds 1%	Mar. 07	MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	Mar. 07	MT
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	Feb. 29	MT
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	Feb. 09	MT
Samsung Biologics's Q4 Net Income Declines	Jan. 24	MT
Samsung Biologics Subsidiary Secures Ministry Approval for Soliris Biosimilar	Jan. 23	MT
Samsung C&T Inks Deal with US-Based Flagship Pioneering for Bio Startup Investment	Jan. 09	MT
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership	Jan. 04	DJ
South Korean shares fall for second day after US Fed minutes	Jan. 03	RE
S.Korean shares fall after Fed minutes; biopharma leads declines	Jan. 04	RE
S.Korean shares hit 19-month high on biopharma, e-commerce boost	Jan. 02	RE
Samsung Bioepis Enters Joint Research Pact with IntoCell	Dec. 06	MT
South Korean shares hit over two-month high on lower US bond yields	Nov. 28	RE
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Samsung Biologics' Net Profit Jumps 86% in Q3	23-10-26	MT
Samsung Biologics and Kurma Partners Announce Strategic Partnership for Development and Manufacturing of Biologics for Kurma's Portfolio Companies	23-10-23	CI
South Korean Shares Close Higher as Investors Eye US Payrolls Data; Samsung Biologics Adds 1%	23-10-06	MT
Samsung Biologics Boosts 2023 Revenue Projection Amid Surging Demand	23-10-06	MT
S.Korean shares climb ahead of US payrolls data; still down for week	23-10-05	RE

Chart Samsung Biologics Co.,Ltd.

Duration

Period

More charts

Company Profile

Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Samsung Biologics Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

780,000 KRW

Average target price

1,036,818 KRW

Spread / Average Target

+32.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
CSL LIMITED	-4.66%	87.53B
BIOGEN INC.	-21.76%	29.48B
UCB	+55.45%	25.43B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	15.59B
INCYTE CORPORATION	-18.49%	11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+4.72%	8.75B
INNOVENT BIOLOGICS, INC.	-8.30%	7.99B

Biopharmaceuticals

Samsung Biologics Co.,Ltd.

Equities

A207940

KR7207940008

Pharmaceuticals

Samsung Biologics to invest $1.5 billion to build a new factory in South Korea

Stocks mentioned in the article

EPS Revisions